Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Patienter som hänvisats till kroniska smärtavdelningen för palliativ behandling med ozonterapi mellan 2026 och 2029. (EPOOzo-2)

22 september 2026 uppdaterad av: Bernardino Clavo, MD, PhD

Prospektiv och observationsstudie av patienter som remitterats till smärtenheten för palliativ behandling med ozonterapi mellan 2026 och 2029. Prospektiv studie EPOOzo-2.

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.

Studieöversikt

Detaljerad beskrivning

Patients are referred to the Chronic Pain Unit in the absence or failure of standard treatment, or when the standard treatment is associated with high morbidity or high risk. Frequently, these patients present alterations in self-perceived health-related quality of life (HRQoL), anxiety, depression, and other symptoms such as radiation-induced pelvic toxicity or chemotherapy-induced peripheral neuropathy (CIPN).

This prospective observational study (EPOOzo-2) aims to evaluate the effect of adjuvant symptomatic/palliative ozone therapy on HRQoL and potential changes from baseline. Specifically, it incorporates new non-invasive technologies to objectively assess microcirculation, neuropathy and autonomic regulation.

Main Objectives:

1. Analyze the impact on HRQoL of patients with refractory symptoms treated with ozone.

Secondary Objectives: Depending on the clinical case, analyze the impact of ozone treatment on: 2. Anxiety and depression. 3. Treated symptoms (e.g., pain, paresthesia). 4. Fatigue. 5. Toxicity grade (in cancer patients). 6. Non-invasive clinical parameters related to the Autonomic Nervous System (central and peripheral) and somatosensory function. 7. Biochemical parameters and gut microbiome analysis (in patients with systemic/rectal ozone).

Methodology: Prospective and observational study of patients referred for symptomatic/palliative ozone therapy between January 2026 and December 2029.

Assessments at weeks: 0 (baseline), 16 (end of O3/O2 treatment), 28 (12 weeks after the end of ozone), and 40 (24 weeks after the end of ozone).

Studietyp

Observationell

Inskrivning (Beräknad)

120

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Francisco Rodríguez-Esparragón, BSc, PhyD
  • Telefonnummer: +34 928449288
  • E-post: afrodesp@gmail.com

Studieorter

    • Las Palmas
      • Las Palmas de Gran Canaria, Las Palmas, Spanien, 35019
        • Rekrytering
        • Dr. Negrín University Hospital
        • Kontakt:
          • Francisco Rodríguez-Esparragón, BSc, PhyD
          • Telefonnummer: +34 928449288
          • E-post: afrodesp@gmail.com
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín, between January 2026 and December 2029, for symptomatic/palliative treatment with ozone therapy because standard treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.

Beskrivning

Inclusion Criteria:

  • 1. Adults ≥ 18 years old.
  • 2. Patients referred to the Chronic Pain Unit of the Dr. Negrín University Hospital for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, has failed, has offered insufficient results, or is associated with high risk/morbidity.
  • 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.
  • 4. Patients have no contraindications for ozone treatment.
  • 5. Patients must sign the specific Informed Consent for this study and for the ozone treatment.

Exclusion Criteria:

  • 1. Age < 18 years old.
  • 2. Psychiatric illness or social situations that would limit compliance with study requirements.

Contraindication or disability to attend scheduled treatments.

  • 3. Contraindication or disability to attend scheduled treatments.
  • 4. Uncontrolled clinical conditions (e.g., severe heart failure, massive hemorrhage, status epilepticus).
  • 5. Life expectancy < 6 months.
  • 6. Known allergy to ozone.
  • 7. Hemochromatosis (for systemic ozone treatment).
  • 8. Pregnancy (for systemic ozone treatment).
  • 9. Significant Glucose-6-Phosphate Dehydrogenase deficiency (Favism) (for systemic ozone treatment).
  • 10. Patients who do not meet the inclusion criteria.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Ozone Group

Patients with refractory symptoms referred for palliative treatment with ozone therapy between 2026 and 2029.

Systemic (rectal, autohemotherapy) and/or local ozone administration (cutaneous, intravaginal, intravesical). Dosage, frequency, and duration will depend on the symptoms treated and clinical evolution. Usually planned 40 sessions over 4 months.

Andra namn:
  • Ozonbehandling

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At the end of ozone therapy (approx. week 16).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 24 weeks after the end of ozone therapy).
Tidsram: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 week after the end of ozone therapy (approx. week 28).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 12 week after the end of ozone therapy (approx. week 28).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 24 weeks after the end of ozone therapy).
Tidsram: At 24 week after the end of ozone therapy (approx. week 40).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 24 week after the end of ozone therapy (approx. week 40).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At the end of ozone therapy (approx. week 16).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 24 weeks after the end of ozone therapy).
Tidsram: At 24 weeks after the end of ozone therapy (approx. week 40).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At the end of ozone therapy (approx. week 16).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 24 weeks after the end of ozone therapy).
Tidsram: At 24 weeks after the end of ozone therapy (approx. week 40).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Pain Score (Visual Analog Scale), (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At the end of ozone therapy (approx. week 16).
Change from Baseline in Pain Score (Visual Analog Scale), (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Pain Score (Visual Analog Scale), (at 24 weeks after the end of ozone therapy).
Tidsram: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At the end of ozone therapy (approx. week 16).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 24 weeks after the end of ozone therapy).
Tidsram: At 24 weeks after the end of ozone therapy (approx. week 40).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Postural Stability (Equilibrium Platform), (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Postural Stability (Equilibrium Platform), (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Heart Rate Variability (HRV), (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Heart Rate Variability (HRV), (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At the end of ozone therapy (approx. week 16).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At the end of ozone therapy (approx. week 16).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Gut Microbiota Composition (at the end of ozone therapy).
Tidsram: At the end of ozone therapy (approx. week 16).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Gut Microbiota Composition (at 12 weeks after the end of ozone therapy).
Tidsram: At 12 weeks after the end of ozone therapy (approx. week 28).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At 12 weeks after the end of ozone therapy (approx. week 28).

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
  • Huvudutredare: Francisco Rodríguez-Esparragón, BSc, PhyD, Dr. Negrín University Hospital, Las Palmas, Spain
  • Huvudutredare: Ángeles Cánovas-Molina, RN, Dr. Negrín University Hospital, Las Palmas, Spain

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 januari 2026

Primärt slutförande (Beräknad)

31 december 2029

Avslutad studie (Beräknad)

30 juni 2030

Studieregistreringsdatum

Först inskickad

23 december 2025

Först inskickad som uppfyllde QC-kriterierna

23 december 2025

Första postat (Faktisk)

8 januari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

  • It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
  • Data will be available after publication, ending 36 months following the article publication.
  • They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

Tidsram för IPD-delning

Data will be available after publication, ending 36 months following article publication.

Kriterier för IPD Sharing Access

They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera